CHEST 2006 ABSTRACT BRIEFS
EMBARGO: Each Abstract is Embargoed Until the Day/Time Listed Below Title
Pulmonary Hypertension Inhaled Iloprost May Increase Airway Obstruction in Children
(Wednesday, October 25, 2006, 12:30 PM EST)
A new study shows that inhaled iloprost, recently introduce to treat pulmonary arterial hypertension (PAH), can lead to acute lower airway obstruction in children. Researchers from both Texas and Denver Children’s Hospitals obtained pre- and post-iloprost inhalation spirometry on 12 children diagnosed with PAH. All patients were on oral pulmonary vasodilator therapy during testing. In all, 5 of the 12 patients experienced a forced expiratory flow decrease of more than 15 percent, and four showed a drop of seven percent or more. Chest pain was also reported as an adverse effect, possibly resulting from airway reactivity following the inhalation of iloprost. Researchers suggest pulmonary function testing be performed on all children with PAH before and after inhaled prostacyclin therapy is initiated.
Inhaled Iloprost Well-Tolerated in Children With PAH
(Wednesday, October 25, 2006, 12:30 PM EST)
Inhaled iloprost administered to children with pulmonary arterial hypertension (PAH) was shown to be safe and effective in a new study from the University of Colorado/Children’s Hospital and Texas Children’s Hospital. Eleven children with PAH were treated with inhaled iloprost five to nine times daily, for 3 to 11 months. Researchers compared pretreatment responses with iloprost vs inhaled nitric oxide during cardiac catheterization. Results showed no change in FEV1 and forced expiratory flow in pulmonary function tests performed pre- and posttreatment. Researchers concluded that iloprost therapy in children with PAH was safe, well tolerated, effective, and predictive of clinical response to chronic therapy.
Thyroid Dysfunction Prevalent in Patients With Pulmonary Hypertension
(Wednesday, October 25, 2006, 2:30 PM EST)
New research suggests that adults with pulmonary hypertension (PH) are more likely to experience thyroid disease than the general population or other patients with comparable pulmonary disease. A study of 358 patients with PH, seen at Mayo-Clinic Jacksonville over a
-more-
14-year period, was performed, and matched controls were randomly selected. Research showed that thyroid disease was present in 31 percent of the PH group, compared with only 15 percent in the control group. Also, at the time of initial PH evaluation, only about 55 percent of patients with hypothyroid were adequately treated. However, despite the high prevalence of thyroid disease, treatment did not seem to affect the severity of the PH. |
